What is HC Wainwright’s Forecast for Harrow Q4 Earnings?

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for shares of Harrow in a report issued on Thursday, February 6th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.00 EPS and FY2025 earnings at ($0.20) EPS.

Separately, B. Riley cut their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

Harrow Stock Performance

Shares of HROW stock opened at $32.00 on Monday. The firm has a 50 day moving average of $34.78 and a 200-day moving average of $39.83. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -34.04 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow has a 52 week low of $9.30 and a 52 week high of $59.23.

Hedge Funds Weigh In On Harrow

A number of large investors have recently modified their holdings of HROW. Quest Partners LLC bought a new stake in Harrow during the 3rd quarter valued at $29,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares during the last quarter. Hills Bank & Trust Co bought a new stake in shares of Harrow during the third quarter worth about $107,000. AlphaQuest LLC raised its holdings in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after acquiring an additional 2,889 shares during the last quarter. Finally, Huntington National Bank bought a new position in Harrow in the 3rd quarter valued at about $164,000. 72.76% of the stock is currently owned by institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.